Exact Sciences Yönetim

Yönetim kriter kontrolleri 2/4

Exact Sciences CEO'su Kevin Conroy, Apr2009 tarihinde atandı, in görev süresi 15.5 yıldır. in toplam yıllık tazminatı $ 16.12M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.5% maaş ve 93.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.39% ine doğrudan sahiptir ve bu hisseler MX$ 974.14M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 5.6 yıldır.

Anahtar bilgiler

Kevin Conroy

İcra Kurulu Başkanı

US$16.1m

Toplam tazminat

CEO maaş yüzdesi	6.5%
CEO görev süresi	15.5yrs
CEO sahipliği	0.4%
Yönetim ortalama görev süresi	3.8yrs
Yönetim Kurulu ortalama görev süresi	5.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Kevin Conroy'un ücretlendirmesi Exact Sciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$175m
Mar 31 2024	n/a	n/a	-US$240m
Dec 31 2023	US$16m	US$1m	-US$204m
Sep 30 2023	n/a	n/a	-US$282m
Jun 30 2023	n/a	n/a	-US$432m
Mar 31 2023	n/a	n/a	-US$517m
Dec 31 2022	US$14m	US$510k	-US$624m
Sep 30 2022	n/a	n/a	-US$716m
Jun 30 2022	n/a	n/a	-US$735m
Mar 31 2022	n/a	n/a	-US$745m
Dec 31 2021	US$15m	US$963k	-US$596m
Sep 30 2021	n/a	n/a	-US$793m
Jun 30 2021	n/a	n/a	-US$829m
Mar 31 2021	n/a	n/a	-US$720m
Dec 31 2020	US$20m	US$499k	-US$824m
Sep 30 2020	n/a	n/a	-US$327m
Jun 30 2020	n/a	n/a	-US$165m
Mar 31 2020	n/a	n/a	-US$136m
Dec 31 2019	US$19m	US$792k	-US$213m
Sep 30 2019	n/a	n/a	-US$216m
Jun 30 2019	n/a	n/a	-US$221m
Mar 31 2019	n/a	n/a	-US$219m
Dec 31 2018	US$7m	US$696k	-US$175m
Sep 30 2018	n/a	n/a	-US$143m
Jun 30 2018	n/a	n/a	-US$124m
Mar 31 2018	n/a	n/a	-US$119m
Dec 31 2017	US$13m	US$633k	-US$114m

Tazminat ve Piyasa: Kevin 'nin toplam tazminatı ($USD 16.12M ), MX pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.75M ).

Tazminat ve Kazançlar: Kevin şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Kevin Conroy (58 yo)

15.5yrs

Görev süresi

US$16,119,899

Tazminat

Mr. Kevin T. Conroy served as Independent Director of SomaLogic, Inc. since September 1, 2021, until January 2022. Mr. Conroy had served as an Independent Director of Adaptive Biotechnologies Corporation s...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kevin Conroy	Chairman of The Board & CEO	15.5yrs	US$16.12m	0.39% MX$ 974.1m
Jake Orville	Executive VP & General Manager of Pipeline	no data	US$3.67m	0.0084% MX$ 21.3m
Brian Baranick	Executive VP & General Manager of Precision Oncology	no data	US$3.57m	0.0072% MX$ 18.1m
Aaron Bloomer	Chief Financial Officer	less than a year	Veri yok	Veri yok
Jorge Garces	Chief Science Officer	3.5yrs	Veri yok	Veri yok
Nassar Nizami	Chief Information Officer	1.8yrs	Veri yok	Veri yok
Megan Jones	Associate Manager of Investor Relations	no data	Veri yok	Veri yok
Tim Caprez	Chief Compliance Counsel & VP	9.8yrs	Veri yok	Veri yok
James Herriott	Senior VP	2.8yrs	Veri yok	0.0060% MX$ 15.1m
Sarah Condella	Executive Vice President of Human Resources	7.4yrs	US$2.71m	0.042% MX$ 107.2m
Graham Lidgard	Emeritus Chief Science Officer	3.8yrs	US$4.21m	Veri yok
Ana Hooker	Chief Laboratory Officer	9.3yrs	US$3.95m	Veri yok

3.8yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim: EXAS * 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kevin Conroy	Chairman of The Board & CEO	15.6yrs	US$16.12m	0.39% MX$ 974.1m
Daniel Levangie	Independent Director	14.3yrs	US$408.75k	0.015% MX$ 38.9m
D. Coward	Director	1.8yrs	US$1.47m	0.030% MX$ 75.0m
Katherine Zanotti	Independent Director	15.5yrs	US$406.25k	0.038% MX$ 95.9m
Michael Barber	Independent Director	less than a year	Veri yok	0.0029% MX$ 7.5m
Paul Clancy	Independent Director	3.6yrs	US$417.75k	0.011% MX$ 27.6m
Kathleen Sebelius	Independent Director	5.6yrs	US$411.75k	0.017% MX$ 43.6m
Shacey Petrovic	Independent Director	4.3yrs	US$401.25k	0.012% MX$ 31.5m
James Doyle	Lead Independent Director	10.3yrs	US$442.75k	0.030% MX$ 76.0m

5.6yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: EXAS * 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.6 yıldır).

Exact Sciences Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Exact Sciences Corporation, Annual General Meeting, Jun 13, 2024

Exact Sciences Corporation Announces Executive Changes

Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Chief Financial Officer in 2024

Recent updates

Exact Sciences Corporation Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2024

Exact Sciences Corporation to Report Q3, 2024 Results on Nov 05, 2024

FDA Approves Exact Sciences Corp.’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening

Exact Sciences Corporation(NasdaqCM:EXAS) dropped from FTSE All-World Index (USD)

Exact Sciences Presents Data Demonstrating Advancement in Blood-Based Colorectal Cancer Screening At ESMO 2024

Exact Sciences Corp. Announces First Patient Enrolled in Its Multi-Cancer Early Detection Falcon Registry Real-World Evidence Study

Second quarter 2024 earnings released: US$0.086 loss per share (vs US$0.45 loss in 2Q 2023)

Exact Sciences Corporation Maintains Revenue Guidance for the Full Year 2024

Exact Sciences Corporation to Report Q2, 2024 Results on Jul 31, 2024

Geneoscopy, Inc. Files Counterclaims Against Exact Sciences

Geneoscopy, Inc. Files Counterclaims Against Exact Sciences

Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations At Asco®

First quarter 2024 earnings released: US$0.60 loss per share (vs US$0.41 loss in 1Q 2023)

Forecast breakeven date pushed back to 2026

Exact Sciences Corporation Maintains Revenue Guidance for the Full Year of 2024

Exact Sciences Corporation, Annual General Meeting, Jun 13, 2024

Exact Sciences Corporation announced that it has received $266.75 million in funding

Exact Sciences Corporation Announces Executive Changes

Exact Sciences Corporation announced that it expects to receive $266.8 million in funding

Exact Sciences Corporation to Report Q1, 2024 Results on May 08, 2024

Exact Sciences Corp. Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer

Exact Sciences Corporation Provides Revenue Guidance for the Year 2024

Exact Sciences Corporation to Report Q4, 2023 Results on Feb 21, 2024

Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Chief Financial Officer in 2024

Exact Sciences Corp. Presents Multiple Studies At San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023

Exact Sciences Corp. Announces Late-Breaking Data from the Pivotal Blue-C Trial

Exact Sciences Corporation to Report Q3, 2023 Results on Nov 01, 2023

Exact Sciences Corporation (NasdaqCM:EXAS) agreed to acquire Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A).

Exact Sciences Corporation (NasdaqCM:EXAS) agreed to acquire Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A).

New minor risk - Shareholder dilution

Forecast to breakeven in 2025

Exact Sciences Corporation Announces Impairment of Long-Lived Assets for the Second Quarter Ended June 30, 2023

Exact Sciences Corporation to Report Q2, 2023 Results on Aug 01, 2023

Exact Sciences Corporation to Report Q2, 2023 Results on Aug 01, 2023

Exact Sciences Corp. Announces Positive Top-Line Results from the Pivotal Blue-C Study

Exact Sciences Corp. Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing at ASCO 2023

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş